Actavis Pain Patch Recall: Fentanyl Transdermal System

November 3, 2010

Press Release – 03 NOV 2010 / Product

Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h

Morristown, NJ – (November 3, 2010) – Further to its previously announced voluntary recall of 18 lots of Fentanyl Transdermal System 25 mcg/hour C-II patches, Actavis is encouraging consumers to return any product in their possession from the October 21, 2010 recall.

Consumers with Actavis 25 mcg/h Fentanyl patches may call 1-877-422-7452 (24 hours/day, 7 days/week) for return instructions and information.

Actavis Fentanyl Pain PatchActavis identified one lot of 25 mcg/hour Fentanyl patches (Control/Lot # 30349) shipped to market that contained one patch that released its active ingredient in laboratory testing faster than the approved specification. An accelerated release of Fentanyl from a 25 mcg/hour patch could lead to adverse events for at-risk patients such as children and the elderly, including excessive sedation, respiratory depression, hypoventilation (slow breathing), and apnea (temporary suspension of breathing).

The Control/Lot number appears on the bottom of the product box and on the black and white side of each individual patch packaging, in the lower left corner.

Recalled Control/Lot #s

30041, Exp 12/2011
30049, Exp 12/2011
30066, Exp 12/2011
30096, Exp 01/2012
30097, Exp 02/2012
30123, Exp 01/2012
30241, Exp 02/2012
30256, Exp 02/2012
30257, Exp 03/2012
30258, Exp 03/2012
30349, Exp 03/2012
30350, Exp 03/2012
30391, Exp 03/2012
30392, Exp 04/2012
30429, Exp 04/2012
30430, Exp 04/2012
30431, Exp 04/2012
30517, Exp 04/2012 

Corium International Inc., a third-party supplier for Actavis, manufactured the recalled patches at its Grand Rapids, Michigan facility. The patches are packaged individually and boxed in quantities of five patches per box.

Fentanyl Transdermal System is indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate release opioids.

As part of the voluntary recall, all wholesalers and retailers were asked to return the product from the listed lots that they may still have on hand or in stock. Actavis also is encouraging consumers to return product in their possession. Fentanyl patches sold by Actavis in Europe are not impacted by the recall.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Actavis Fentanyl Pain Patch Overdose Lawsuit Attorney

Poorly designed and dangerous devices and medications such as the Actavis fentanyl pain patch, or any other defective fentanyl pain patch, may cause accidental overdose or other severe and devastating injuries or death.

If you or a loved one has been severely injured as a result of an Actavis fentanyl pain patch or other fentanyl pain patch, talk to an Actavis Fentanyl Pain Patch Lawsuit Attorney at the Willis Law Firm for legal advice about a potential Fentanyl Pain Patch lawsuit.  You are not alone.  Join other Actavis fentanyl pain patch victims and their families in fighting for their legal rights. It may be too late to recover from some of the devastating effects of the Actavis Fentanyl Pain Patch, but an experienced pharmaceutical products liability attorney at the Willis Law Firm can assist you in a legal action against the makers of the Actavis Fentanyl Pain Patch and in filing a Fentanyl Pain Patch Lawsuit.

Please fill out the Free Case Evaluation to the right or call us toll-free at 1-800-883-9858 for immediate help. Please keep in mind that certain states have a statute of limitations that limits the amount of time you have to file an Actavis Fentanyl Pain Patch lawsuit or to seek legal action. Contact our law firm immediately so we may explain the rights and options available to you and your family.

© Willis Law Firm for Drug Attorneys. Replication strictly prohibited without written consent.